Description |
Momordicoside G (Momordicacoside G) is an orally active cucurbitane-type triterpene glycoside. Momordicoside G selectively induces apoptosis of M1-like macrophages, without affecting M2-like macrophages. Momordicoside G reduces intracellular ROS levels and promotes autophagy. Momordicoside G also has anticancer activity, inhibiting the growth of cancer cell lines. Momordicoside G stimulates M2-associated lung injury repair and prevents inflammatory lung cancer injury[1].
|
In Vitro |
用 10 ng/mL LPS 或 10 ng/mL IL-10 刺激 Raw264.7 巨噬细胞 24 h,获得 M1 样 (iNOS+) 和 M2样 (精氨酸酶+) 巨噬细胞[1]。 Momordicoside G (10-40 μM; 24 h) 抑制 M1 巨噬细胞的细胞活力,对 M2 巨噬细胞无抑制作用。Momordicoside G (40 μM) 体外诱导 M1 巨噬细胞凋亡,降低 NO 水平,增加 IL-12、IL-10 和 TGF-β 水平[1]。 Momordicoside G (40 μM) 可抑制细胞自噬相关标志物 LC3-B 的蛋白水平[1]。 Cell Viability Assay[1] Cell Line: M1 macrophages, M2 macrophages Concentration: 10 μM, 20 μM, 40 μM Incubation Time: 24 hours Result: Selectively decreased the cell viability of M1 macrophages, instead of M2 macrophages.
|
In Vivo |
ICR 小鼠的肺部致癌模型由氨基甲酸乙酯 (HY-B1207) (600 mg/kg;腹腔注射;每周一次,持续 4 或 8 周) 诱导,或由 LPS (HY-D1056) (2 mg/kg;气管内施用) 和 4 mg/小鼠 IEC (腹腔注射) 诱导[1]。 Momordicoside G (50 mg/kg;口服;每天一次,持续 4 或 8 周) 在小鼠肺致癌模型中可预防氨基甲酸乙酯引起的肺损伤和癌病变[1]。 Momordicoside G (50 mg/kg;口服;每天一次,持续 2 周) 在 LPS 诱导的肺损伤模型中促进肺损伤修复[1]。 Animal Model: Mouse lung carcinogenic model: Urethane-induced lung carcinogenic model and LPS-induced lung injury model[1] Dosage: 50 mg/kg Administration: Oral gavage; once daily for 4 or 8 weeks Result: Affected inflammasome and cytokines during urethane-induced lung injury and carcinoma lesions. Exhibits macrophage-regulating capacity in LPS-induced lung injury model.
|
Density | 1.2±0.1 g/cm3 |
Boiling Point | 711.4±60.0 °C at 760 mmHg |
Flash Point | 384.0±32.9 °C |
Exact Mass | 632.428833 |
PSA | 117.84000 |
LogP | 5.40 |
Vapour Pressure | 0.0±5.2 mmHg at 25°C |